Abstract:Introduction: Immune escape frequently occurs and restricts the durability of the antitumor immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important immune checkpoint molecules that could cause tumor cells to escape the host immune response. The aim of the study was to explore the role of PD-L1 in radioresistance and the antitumor effect of combined radiotherapy and anti-PD-L1 therapy in NSCLC.Methods: The role of the phosphoinositide 3-kinase/protein kinase B signal transducer and activator of transcription 3, epithelial-mesenchymal transition, and tripartite motif containing 21 in regulating PD-L1 expression after radiotherapy was investigated by small interfering-PD-L1 RNA transfection, immunohistochemistry, Western blot, and immunoprecipitation. The synergistic effect of radiotherapy and anti-PD-L1 antibody was evaluated in a mouse model. PD-L1 expression on tumor specimens was examined in a retrospective cohort of patients who received concurrent chemoradiotherapy.Results: PD-L1 expression was increased in vivo and in vitro after conventionally fractionated radiation. Radiotherapy in combination with anti-PD-L1 antibody synergistically enhanced antitumor immunity by promoting CD8-positive T cell infiltration and reducing the accumulation of myeloid derived suppressor cells and tumor-infiltrating regulatory T cells in a mouse model. Radiotherapy may up-regulate PD-L1 expression through the phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3 pathways. PD-L1 may also stimulate cell migration and facilitate the epithelial-mesenchymal transition process to induce radioresistance. Moreover, down-regulating PD-L1 could alleviate radioresistance' by promoting apoptosis. Intriguingly, patients with negative PD-L1 expression had a significantly higher objective response rate (88% versus 43.1% [p < 0.001]) and disease control rate (100% versus 86.2% [p = 0.026]) than those with positive PD-L1 expression after delivery of radiotherapy.Conclusions: Conventionally fractionated radiotherapy in combination with anti-PD-L1 antibody shows a synergistic antitumor immunity in NSCLC. Furthermore, PD-L1 expression may be a significant clinical predictive factor for treatment response to radiotherapy in NSCLC. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.

Enhancement of Radiation Sensitivity by Erlotinib and Celecoxib in A549 Human Lung Cancer Cell Line

Celecoxib and Afatinib Synergistic Enhance Radiotherapy Sensitivity on Human Non-Small Cell Lung Cancer A549 Cells

Celecoxib Enhances the Sensitivity of Non-Small-cell Lung Cancer Cells to Radiation-Induced Apoptosis Through Downregulation of the Akt/mTOR Signaling Pathway and COX-2 Expression

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Celecoxib Enhances Radiosensitivity Via Induction of G2-M Phase Arrest and Apoptosis in Nasopharyngeal Carcinoma

Effect of Taxotere Combination with Celecoxib on Proliferation of NSCLC Cell

Celecoxib's Radiosensitizing Effects on Three Different Human Cancer Cell Lines

Radiosensitization of Celecoxib on Human Lung Adenocarcinoma Cell Line A549 and Inhibition of Migration Ability in Vitro

Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study

Inhibition of Cyclooxygenase‑2 Sensitizes Lung Cancer Cells to Radiation‑induced Apoptosis

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody

Synergistic inhibitory effect of erlotinib and celecoxib on the growth of cholangiocarcinoma cells

Combination of S-1 and Gefitinib Increases the Sensitivity to Radiotherapy in Lung Cancer Cells

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells

The Different Radiosensitivity when Combining Erlotinib with Radiation at Different Administration Schedules Might Be Related to Activity Variations in C-Met-pi3k-akt Signal Transduction.

The Depressive Effect of Detected on the Proliferation of A549 Human Lung Adenocarcinoma Cell Lines and Celecoxib Combined with Cisplatin or X-ray

Radiosensitivity Enhancement by Combined Treatment of Nimotuzumab and Celecoxib on Nasopharyngeal Carcinoma Cells

Combined Cetuximab and Celecoxib Treatment Exhibits a Synergistic Anticancer Effect on Human Oral Squamous Cell Carcinoma in Vitro and in Vivo

Effect of Celecoxib on Inhibiting Tumor Repopulation During Radiation Therapy in Human FaDu Squamous Cell Carcinoma